Fate Therapeutics (NASDAQ:FATE) has received an average recommendation of “Buy” from the eleven analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $16.17.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research upgraded Fate Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Friday, January 19th. Wedbush restated an “outperform” rating and issued a $19.00 price target on shares of Fate Therapeutics in a research note on Thursday, March 29th. BidaskClub upgraded Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. UBS cut Fate Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 6th. Finally, HC Wainwright reiterated a “hold” rating and set a $12.00 price objective on shares of Fate Therapeutics in a research report on Tuesday, March 20th.

How to Become a New Pot Stock Millionaire

FATE opened at $11.15 on Friday. Fate Therapeutics has a 1-year low of $2.52 and a 1-year high of $14.45. The company has a debt-to-equity ratio of 0.19, a current ratio of 9.29 and a quick ratio of 9.29.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). Fate Therapeutics had a negative net margin of 1,046.08% and a negative return on equity of 71.00%. The business had revenue of $1.03 million during the quarter, compared to the consensus estimate of $1.02 million. The business’s revenue was up .0% on a year-over-year basis. equities research analysts predict that Fate Therapeutics will post -0.94 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of FATE. Raymond James & Associates bought a new position in Fate Therapeutics during the 4th quarter worth $141,000. The Manufacturers Life Insurance Company increased its position in Fate Therapeutics by 61.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 33,337 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 12,686 shares during the period. California State Teachers Retirement System bought a new position in Fate Therapeutics during the 2nd quarter worth $219,000. Russell Investments Group Ltd. bought a new position in Fate Therapeutics during the 3rd quarter worth $234,000. Finally, Two Sigma Advisers LP increased its position in Fate Therapeutics by 257.0% during the 4th quarter. Two Sigma Advisers LP now owns 71,400 shares of the biopharmaceutical company’s stock worth $436,000 after buying an additional 51,400 shares during the period. Hedge funds and other institutional investors own 66.41% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.dailypolitical.com/2018/04/17/brokerages-set-fate-therapeutics-fate-target-price-at-16-17.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.